New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for la ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

A new drug for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep cancer at bay, a phase I trial reports. The ‘search and destroy’ treatment shrank ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

The biotech industry has delivered an upbeat performance so far in 2026 despite an uncertain macroeconomic backdrop. Strong fourth-quarter results, better visibility, new drug approvals and ...

Penis Botox isn't all that uncommon these days and is chosen for a range of reasons. Tech entrepreneur Bryan Johnson revealed ...

And it costs all of us ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Clinically low testosterone can lead to a range of issues, including low energy, depressed mood, and brain fog, and it can be treated with TRT. However, a growing number of men are turning to ...